This poster, presented at AACR 2022 from Prognomiq, describes a proof-of-concept study using broad phenotypic multi-omics approach to identify known and unknown biomarkers in a pancreatic cancer cohort.
This poster, presented at USHUPO from Prognomiq describes how Seer’s Proteograph™ nanoparticle technology specifically captures unique proteoforms in the corona formation and allow for comprehensive assessment of the circulating glycoproteome.
This study examines in detail the relationship between the unique physicochemical properties of a panel of proprietary engineered nanoparticles (NPs) and the diverse pattern of protein sampling that is enabled by a unique nano-bio interface that is created between a given NP surface and a given biological sample.
This poster, presented at USHUPO describes a performance evaluation between label-free and tandem mass tag multiplex methods for plasma proteomics. The Proteograph Product Suite enables rapid, automated and reproducible sample prep for larger sample cohorts.
Presented at USHUPO 2022, this study describes how nano-bio interactions may be tuned to optimize the binding and capture of a large and diverse set of proteins, including cytokines and hormone signaling proteins.
This article explores the unique capacity of nanoparticles, a key component of the Proteograph Product Suite, to be tuned to interact with proteins by tailored surface functionalization and optimized to enable deeper protein access.
This poster presented at the American Society for Mass Spectrometry describes a high-throughput multiplexed workflow for 16 biofluid samples. Plasma proteins across 9 orders of magnitude dynamic range including 40 cytokine activity proteins and several members of the TNF superfamily were identified.
This collaboration with the Broad Institute presented at the American Society for Mass Spectrometry describes a Proteograph™ application for cardiovascular biomarker research using deep plasma proteomics. Over 2000 proteins were detected in each individual patient sample with a total of over 4000 across 16 samples.
This poster presented at the American Society for Mass Spectrometry from Oregon Health Sciences University describes a Proteograph™ application proof-of-concept pilot study on 32 prostate cancer serum specimens retrospectively collected from patients with high and low tumor grades.